- See our full panel of Cardiac Safety Assays including binding assays for quick screening, functional tissue and in vivo assays for secondary profiling data and IND enabling GLP assays
- Empower lead selection and optimization with the ability to better predict cardiac liability earlier in the drug development process
- Functional patch clamp assays with the assurance of gold-standard electrophysiology data - scaled to meet the needs of discovery phase R&D
- Mandatory FDA regulated GLP hERG assay enables timely IND submissions
- S7B suggested Purkinje Fiber APD assay assesses multi-channel effects
- Access to scientific expertise and technical support for data interpretation
Detect Cardiac Safety Liabilities Early
Inhibition of each of the key cardiac ion channels that encode the major currents can have dramatic affects on the cardiac action potential waveform. Inhibition of the hERG channel (IKr) can result in prolongation of the action potential, and may be associated with torsade de pointes (TdP). Inhibition of the hNav1.5 channel (INa) can result in shortening of both the peak amplitude and duration of the action potential, and may be associated with arrhythmias, and sudden death.
|
|
|
Inhibition of the hCav1.2 (ICa) can result in shortening the duration of the action potential, and is associated with reduced conduction and contractility, bradycardia and arrhythmias. When pharmaceuticals for non-cardiovascular use block any of these channels, independently or in concert, the effects on the cardiac waveform can be life threatening, presenting an unacceptable risk.
|
|